| 000 | 01387 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250517205257.0 | ||
| 264 | 0 | _c20181001 | |
| 008 | 201810s 0 0 eng d | ||
| 022 | _a1875-8592 | ||
| 024 | 7 |
_a10.3233/CBM-170795 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZhou, Xin | |
| 245 | 0 | 0 |
_aEvaluation of neutrophil-to-lymphocyte ratio in newly diagnosed patients receiving borte- zomib-based therapy for multiple myeloma. _h[electronic resource] |
| 260 |
_bCancer biomarkers : section A of Disease markers _c2018 |
||
| 300 |
_a43-48 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBortezomib _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphocytes _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Myeloma _xblood |
| 650 | 0 | 4 |
_aNeutrophils _xdrug effects |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRetrospective Studies |
| 700 | 1 | _aWang, Jing | |
| 700 | 1 | _aXia, Jun | |
| 700 | 1 | _aCheng, Feng | |
| 700 | 1 | _aMao, Jingjue | |
| 700 | 1 | _aZhu, Jianwei | |
| 700 | 1 | _aGuo, Hongfeng | |
| 773 | 0 |
_tCancer biomarkers : section A of Disease markers _gvol. 22 _gno. 1 _gp. 43-48 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3233/CBM-170795 _zAvailable from publisher's website |
| 999 |
_c28201712 _d28201712 |
||